# A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

> **NCT00106535** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1196 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]
- **DRUG:** Placebo
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00106535
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-05
- **Final completion:** 2012-07
- **Target enrollment:** 1196 (ACTUAL)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106535, "A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00106535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*